Latest news with #Respilon
Mint
28-04-2025
- Business
- Mint
Pharma stock jumps 5% from today's low after this MoU update. Do you own?
Pharmaceuticals sector stock Sigachi Industries bounced back 5 per cent from its intraday low after a wholly owned subsidiary of the company, on Monday, April 28, signed a memorandum of understanding (Mou) with Respilon Group to work on nanofiber-based drug delivery technologies, according to an exchange filing. 'Sigachi Industries Limited, a leading player in pharmaceutical industry is pleased to announce that its wholly owned subsidiary, Sigachi MENA FZCO, has signed a Memorandum of Understanding (MoU) with Respilon Group s.r.o to advance nanofiber-based drug delivery technologies,' said the company in the BSE filing. According to the filing data, the company aims to leverage Respilon's patented nanofiber technology to transform the patient experience and therapeutic outcomes as the firm seeks to deliver a non-invasive, precision drug delivery system. 'Partnering with Respilon aligns perfectly with our vision to deliver next-generation pharmaceutical solutions that improve therapeutic outcomes and elevate the patient experience. We are excited about the possibilities NUENEX® technology offers to revolutionize drug delivery systems globally,' said Amit Raj Sinha, the managing director and chief executive officer of Sigachi Industries. The strategic collaboration also includes developing commercialisation strategies for relevant APIs and formulations, leveraging nanofiber encapsulation technology, according to the exchange filing. Sigachi Industries shares hit an intraday high of ₹ 43.93 after the company announced the MoU update on Monday. The shares gained an overall 5.09 per cent to hit those highs from today's low of ₹ 41.80 per share. The shares closed 1.10% higher at ₹ 43.29 after the stock market session on Monday, April 28, compared to ₹ 42.82 at the previous stock market close, according to the BSE data. Sigachi Industries shares have given stock market investors 22.91 per cent returns in the last one-month period, and the stock is currently trading above its year-low levels, which it hit in February 2025. The shares hit their 52-week high level at ₹ 75.45 on May 27, 2025, while the 52-week low level was at ₹ 34.51 on February 17, 2025, according to the data collected from the BSE website.
Business Standard
28-04-2025
- Business
- Business Standard
Sigachi Industries inks MoU with Czech Republic-based Respilon Group
Sigachi Industries said that its wholly owned subsidiary Sigachi MENA FZCO has signed a memorandum of understanding (MoU) with Respilon to expand into advanced drug delivery technologies. Headquartered in the Czech Republic, Respilon is an innovation-driven nanofiber R&D company. Sigachi and Respilon will collaborate to develop, manufacture, and commercialize drug delivery solutions based on Respilons proprietary NUENEX nanofiber technology. The two entities would focus on the development of Invisible Patch and Powder-based pharmaceutical delivery formats. The collaboration includes developing commercialization strategies for relevant APIs and formulations, leveraging nanofiber encapsulation technology. Amit Raj Sinha, managing director and CEO of Sigachi Industries, said: "Partnering with Respilon aligns perfectly with our vision to deliver next-generation pharmaceutical solutions that improve therapeutic outcomes and elevate the patient experience. We are excited about the possibilities NUENEX technology offers to revolutionize drug delivery systems globally. Telangana-based Sigachi Industries is engaged in the manufacturing of microcrystalline cellulose (MCC), which is widely used in the pharmaceutical, food, beverage, cosmetic, and paint industries. The most common uses of MCC are in vitamin supplements and tablets. It also acts as a bulking agent in food production. MCC is produced from refined wood pulp, which is imported by the company. The company reported 32.52% jump in consolidated net profit to Rs 21.35 crore in Q3 FY25 from Rs 16.11 crore posted in Q3 FY24. Revenue from operations grew by 25.66% to Rs 139.41 crore in Q3 FY25 from Rs 110.94 crore registered in Q3 FY24. The scrip rose 0.30% to currently trade at Rs 42.95 on the BSE.
Business Standard
28-04-2025
- Business
- Business Standard
Sigachi MENA FZCO signs MoU with Czech Republic-based Respilon
Sigachi MENA FZCO, a wholly owned subsidiary of Sigachi Industries, has signed a Memorandum of Understanding (MoU) with Respilon, an innovation-driven nanofiber R&D company headquartered in the Czech Republic. This partnership marks a significant milestone in Sigachi's strategy to expand into advanced drug delivery technologies. Sigachi and Respilon will collaborate to develop, manufacture, and commercialize drug delivery solutions based on Respilon's proprietary NUENEX nanofiber technology. The collaboration includes developing commercialization strategies for relevant APIs and formulations, leveraging nanofiber encapsulation technology.
Mint
28-04-2025
- Business
- Mint
Pharma stock jumps 5% from today's low this MoU update. Do you own?
Pharmaceuticals sector stock Sigachi Industries bounced back 5 per cent from its intraday low after a wholly owned subsidiary of the company, on Monday, April 28, signed a memorandum of understanding (Mou) with Respilon Group to work on nanofiber-based drug delivery technologies, according to an exchange filing. 'Sigachi Industries Limited, a leading player in pharmaceutical industry is pleased to announce that its wholly owned subsidiary, Sigachi MENA FZCO, has signed a Memorandum of Understanding (MoU) with Respilon Group s.r.o to advance nanofiber-based drug delivery technologies,' said the company in the BSE filing. According to the filing data, the company aims to leverage Respilon's patented nanofiber technology to transform the patient experience and therapeutic outcomes as the firm seeks to deliver a non-invasive, precision drug delivery system. 'Partnering with Respilon aligns perfectly with our vision to deliver next-generation pharmaceutical solutions that improve therapeutic outcomes and elevate the patient experience. We are excited about the possibilities NUENEX® technology offers to revolutionize drug delivery systems globally,' said Amit Raj Sinha, the managing director and chief executive officer of Sigachi Industries. The strategic collaboration also includes developing commercialisation strategies for relevant APIs and formulations, leveraging nanofiber encapsulation technology, according to the exchange filing. Sigachi Industries shares hit an intraday high of ₹ 43.93 after the company announced the MoU update on Monday. The shares gained an overall 5.09 per cent to hit those highs from today's low of ₹ 41.80 per share. The shares are currently trading 0.89 per cent higher at ₹ 43.20 during the afternoon trading session on April 28, compared to ₹ 42.82 at the previous stock market close, according to the BSE data. Sigachi Industries shares have given stock market investors 22.91 per cent returns in the last one-month period, and the stock is currently trading above its year-low levels, which it hit in February 2025. The shares hit their 52-week high level at ₹ 75.45 on May 27, 2025, while the 52-week low level was at ₹ 34.51 on February 17, 2025, according to the data collected from the BSE website. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions. First Published: 28 Apr 2025, 03:16 PM IST
Business Upturn
28-04-2025
- Business
- Business Upturn
Sigachi Industries arm signs MoU with Respilon Group for nanofiber-based drug delivery
By Aditya Bhagchandani Published on April 28, 2025, 12:15 IST Shares of Sigachi Industries Ltd could be in focus after the company announced a key strategic development on Monday. The company's wholly-owned subsidiary, Sigachi MENA FZCO, has signed a Memorandum of Understanding (MoU) with Czech Republic-based Respilon Group s.r.o. to collaborate on advancing nanofiber-based drug delivery technologies. Under the agreement, Sigachi and Respilon will jointly develop, manufacture, and commercialize drug delivery solutions based on Respilon's proprietary NUENEX® nanofiber technology. This partnership focuses on creating next-generation pharmaceutical delivery formats like the Invisible Patch and Powder-based formulations, which aim to improve therapeutic outcomes and elevate the patient experience through non-invasive, precision drug delivery. The MoU was signed on April 24, 2025, between Mr. Lijo Chacko, Managing Director of Sigachi MENA FZCO, and Mr. Roman Zima, Chief Business Officer of Respilon Group, during a formal ceremony. Key highlights of the collaboration: Focus on developing Invisible Patch and powder-based drug delivery systems. Commercialization strategies to be built around nanofiber encapsulation technology for APIs and formulations. Strengthening Sigachi's global presence in advanced drug delivery technologies. Commenting on the development, Mr. Amit Raj Sinha, Managing Director and CEO of Sigachi Industries, said, 'Partnering with Respilon aligns perfectly with our vision to deliver next-generation pharmaceutical solutions that improve therapeutic outcomes and elevate the patient experience.' Mr. Roman Zima of Respilon also expressed optimism, stating that Sigachi's deep industry expertise and global reach would accelerate the deployment of NUENEX® technology across pharmaceutical markets worldwide. About Sigachi Industries: Sigachi is a global player specializing in Active Pharmaceutical Ingredients (APIs), excipients, vitamin-mineral blends, and nutraceutical solutions, with manufacturing units across Telangana, Gujarat, and Karnataka. It operates in over 65 countries and has subsidiaries in the UAE and USA. About Respilon Group: Respilon, headquartered in the Czech Republic, specializes in nanofiber applications across health protection and pharmaceutical sectors, and operates in more than 46 countries. Disclaimer: This article contains forward-looking statements based on current expectations. Actual results may differ due to risks and uncertainties. Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
